On June 24, CARsgen Therapeutics (02171.HK) declined 6.03% in regular trading, trading at HKD 14.7/share, with turnover of HKD 42.98 million. This marked the second consecutive session of significant losses following a 6.36% drop the previous day.
The selloff comes paradoxically after a landmark achievement: on June 22, the company announced that its self-developed CAR-T product Satri-cel (generic name: Sutruicabtagene Autoleucel) received NMPA approval, becoming the world's first CAR-T therapy approved for solid tumors. The product is indicated for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after at least two prior lines of therapy, priced at RMB 990,000 per dose.
Market concerns appear centered on commercial viability. Phase II data showed median PFS improving from 1.77 to 3.25 months and OS from 5.49 to 7.92 months — modest absolute gains. The company projects peak sales of RMB 2 billion within 4-5 years with approximately 200 orders expected this year. Notably, the stock initially surged 8% at open on June 23 before reversing sharply, suggesting a classic sell-the-news pattern. Meanwhile, sector peers including Akeso (+3.8%), Innovent Bio (+4.05%), and BeiGene (+3.48%) all posted gains on June 24, highlighting CARsgen's relative underperformance.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments